Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Exelixis
Scientific Title
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (Other ID's: XL184-309)